Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products

 
• By Brenda Sandburg

Companies used to be able to pick which overlapping products to divest to get US Federal Trade Commission merger approval but an FTC study showed certain divestitures weren't working.

WASHINGTON, DC - SEPTEMBER 28, 2013: Federal Trade Commission Building in Washington, DC.
FTC Requirements for the Celgene/Bristol-Myers Squibb Merger Reflect its Policy Shift on asset divestment.

More from Compliance

More from Pink Sheet